Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types

Fig. 1

Analysis of EBF3 and TBC1D16 methylation in melanoma. a Gene maps for EBF3 (left) and TBC1D16 (right) show RRBS fragments (blue bars) and CpG sites (red asterisks) in relation to the transcription start site (TSS, black arrow), exon 1 (green box) and subsequent exons (gold boxes) of these genes. b Methylation analysis of EBF3 and TBC1D16 CpG sites in a melanoma dataset (accession number GSE44661 [12]) of normal melanocyte samples (M, n = 3, blue boxplots on the left), primary melanoma tumours (P, n = 4, red boxplots), lymph node metastases (LN, n = 17, green boxplots) and brain metastases (BM, n = 16, magenta boxplots); *P < 0.05, **P < 0.01. c DNA methylation patterns in TBC1D16 from primary (purple) and matched metastatic (orange) melanoma cell lines derived from RRBS data. For EBF3 promoter data from matched primary and metastatic melanoma cell line pairs, refer to Chatterjee et al. [9]. The cg17295878 site (marked with a green box) directly overlaps with a CpG site analysed in the melanoma tissue dataset above. Low to high methylation is shown as a continuous variable from blue (0) to white (0.5) to red (1)

Back to article page